Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)

Investigator Site 9, Ancona

Investigator Site 11, Arezzo

Investigator Site 7, Cagliari

Investigator Site 15, Catania

Investigator Site 14, Erice

Investigator Site 4, Genova

Investigator Site 6, L’Aquila

Investigator Site 12, Milan

Investigator Site 2, Modena

Investigator Site 13, Napoli

Investigator Site 10, Novara

Investigator Site 16, Parma

Investigator Site 18, Perugia

Investigator Site 19, Reggio Calabria

Investigator Site 17, Roma

Investigator Site 3, Roma

Investigator Site 5, Roma

Investigator Site 1, Rozzano (MI)

Investigator Site 8, Torino

Investigator Site 14, A Coruña

Investigator Site 18, Albacete

Investigator Site 12, Alicante

Investigator Site 20, Barcelona

Investigator Site 2, Barcelona

Investigator Site 3, Barcelona

Investigator Site 4, Barcelona

Investigator Site 16, Granada

Investigator Site 22, Granada

Investigator Site 1, Las Palmas

Investigator Site 19, Madrid

Investigator Site 21, Madrid

Investigator Site 6, Madrid

Investigator Site 7, Madrid

Investigator Site 8, Madrid

Investigator Site 9, Madrid

Investigator Site 13, Pontevedra

Investigator Site 11, Valencia

Investigator Site 17, Valencia

Investigator Site 15, Zaragoza